Yorvipath (palopegteriparatide) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of hypoparathyroidism (ICD-10 D82.1, E83.5, or E20, excluding E20.1)
• prescriber attests albumin-corrected serum calcium level ≥ 7.8 mg/dL
• member has established hypoparathyroidism despite treatment with calcium and active forms of vitamin D (e.g., calcitriol or alfacalcidol)

Reauthorization criteria

• prescriber attests improvement in total serum calcium from baseline

Approval duration

initial 6 months, reauthorization 12 months